SOD1 and amyotrophic lateral sclerosis: In contrast, while the SOD1 transgenics have been workhorses in the field of ALS research and necessary for development of current potential therapies including anti-SOD1 ASOs, they usually have a fast disease course and are not necessarily an appropriate model for studying pre-symptomatic stages of disease [40].